Q-omics provides the consensus-scored POMGNT1 profile across patient tissues and cancer cell-line models. POMGNT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, POMGNT1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, POMGNT1 protein abundance shows 25,559 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, HNSC, and LUAD as cancer lineages where POMGNT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POMGNT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POMGNT1 survival associations across molecular data types. POMGNT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POMGNT1 RNA expression–survival associations across cancer types. High POMGNT1 expression shows unfavorable associations in LIHC, MESO, LGG and SKCM, but favorable associations in UVM and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for POMGNT1 RNA expression.
This table summarizes POMGNT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POMGNT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POMGNT1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, COAD and LIHC. The HNSC box plot shows higher POMGNT1 RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with POMGNT1 in patient tissues and cancer cell lines. In patient samples, POMGNT1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, POMGNT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
